Document:

<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.19
                                                                     S87-012:LRM
                                                                  Patent License
                                                                         3/26/97

                             CO-EXCLUSIVE AGREEMENT

Effective as of APRIL 23, 1997, THE BOARD OF TRUSTEES OF THE LELAND STANFORD
JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State
of California, having a principal place of business at 900 Welch Road, Suite
350, Palo Alto California ("STANFORD"), and GEN-PROBE Incorporated, a
corporation organized and existing under the laws of the State of Delaware and
having a principal place of business at 9880 Campus Point Drive, San Diego,
California ("GEN-PROBE"), agree as follows:

1. BACKGROUND

1.1  STANFORD represents that it owns an assignment of all rights, titles and
     interest to the technique of Selective Amplification of Target
     Polynucleotide Sequences ("Invention"), as described in Stanford Docket
     S87-012 and pursuant to 35 U.S.C. 202, and any Licensed Patent(s), as
     hereinafter defined, which may issue to such Invention.

1.2  STANFORD has rights to certain technical data and information pertaining
     to Invention.

1.3  STANFORD wishes to have the Invention perfected and marketed at the
     earliest possible time in order that products resulting therefrom may be
     available for public use and benefit.

1.4  The Invention was made in Dr. John Boothroyd's laboratory during the course
     of research supported by the National Institutes of Health.

1.5  Gen-Probe, Inc. is a licensee of STANFORD under Licensed Patent(s) under a
     license agreement dated August 1, 1988 and an amendment thereto dated June
     19, 1993 (collectively the "Original Amended License Agreement").

1.6  GEN-PROBE and Organon Teknika B.V. desire that both GEN-PROBE and Organon
     Teknika B.V., become Co-Exclusive licensees under Licensed Patent(s).

                                      -1-
<PAGE>
1.7  STANFORD desires to grant a Co-Exclusive license to GEN-PROBE in
     recognition of:

          (a)  GEN-PROBE's agreement to allow its Original Amended License
               Agreement to be amended to allow STANFORD to grant a Co-Exclusive
               license to Organon Teknika B.V. provided that:

                    (i)  Organon-Teknika is the only other Co-Exclusive
                         licensee;

                   (ii)  the Co-Exclusive license to Organon Teknika includes
                         the right to grant sublicenses;

                  (iii)  the scope of Organon Teknika's Co-Exclusive license is
                         no broader than the Original Amended License Agreement;

                   (iv)  the terms of any such Co-Exclusive license concluded
                         between Organon Teknika and STANFORD will be made
                         available by STANFORD to GEN-PROBE, at GEN-PROBE's
                         option; and

                    (v)  the terms of any Co-Exclusive license concluded
                         between GEN-PROBE and STANFORD will be made available
                         by STANFORD to Organon Teknika, at Organon-Teknika's
                         option.

          (b)  An interference settlement concerning STANFORD's US Patent No.
               5,437,990 issued August 1, 1995 and associated foreign patent
               oppositions (collectively, "The '990 Arbitration").

1.8  GEN-PROBE, for its agreement to the terms hereunder, and for its agreement
     to be bound to the terms of this Agreement regardless of the outcome of the
     '990 Arbitration wishes to acquire license under said Invention and
     Licensed Patent(s), for the purpose of undertaking development, to
     manufacture, use, and sell Licensed Products(s) in the

                                      -2-

<PAGE>
     Licensed Field of Use, Licensed Product(s) and Licensed Field of Use being
     terms hereinafter defined.

2. DEFINITIONS

2.1  "Licensed Patent(s)" means US Patent No. 5,437,990 issued on August 1, 1995
     and any Letters Patent issued upon STANFORD's U.S. Patent Application,
     Serial Number 080,479 filed July 31, 1987, including the information
     contained in such application, with respect to the Invention, any foreign
     patents corresponding thereto, and/or any divisions, continuations, or
     continuations-in-part, or reissue thereof.

2.2  "Licensed Product(s)" means any product or part thereof in the Licensed
     Field of Use, the manufacture, use, or sale of which:

          (a)  Is covered by valid claim of an issued, unexpired Licensed
               Patent(s) directed to the Invention. A claim of an issued,
               unexpired Licensed Patent(s) shall be presumed to be valid unless
               and until it has been held to be invalid by a final judgment of a
               court of competent jurisdiction from which no appeal can be or is
               taken;

          (b)  Is covered by any claim being prosecuted in a pending
               application directed to the Invention.

     For the avoidance of doubt, GEN-PROBE herewith confirms that in the event a
     Siska patent (i.e., a patent issuing from U.S. application Nos.
     07/845,739,07/202,978, or 07/064,141 or any application related thereto)
     prevails in the '990 Arbitration GEN-PROBE shall continue to pay royalties,
     as per Paragraph 6.2, on any product that would otherwise be included in
     the definition of Licensed Product(s) under this Paragraph 2.2 without
     regard to the outcome of the '990 Arbitration.

2.3  "Net Sales" means the gross revenue of the Licensed Product(s) in the form
     in which it is sold or used, whether or not assembled (and without
     excluding therefrom any components or subassemblies thereof, whatever their
     origin and whether or not patent impacted), less the following items but
     only insofar as they actually pertain to the

                                      -3-

<PAGE>
     disposition of such Licensed Product(s) by GEN-PROBE and/or sublicensee(s)
     and are included in such gross income, and (except Items (d) and (e)) are
     separately billed:

          (a)  Import, export, excise, and sales taxes, plus custom duties;

          (b)  Cost of insurance, from the place of manufacture or point of
               installation, packing, and transportation to the customer's
               premises or point of installation;

          (c)  Costs of installation at the place of use;

          (d)  Credit for returns, rejections, recalls, allowances, or trades;
               and

          (e)  a reasonable allocation for the rental of an instrument when the
               product is sold under a reagent rental program, except where the
               instrument is a Licensed Product.

2.3.1  In the case where GEN-PROBE sells a Combination Product, prior to
       calculating the royalty under Section 6.2, Net Sales of the Combination
       Product shall be multiplied by the formula A/B where A is the gross
       selling price of a Licensed Product sold separately which performs a
       function of the Combination Product and B is the gross selling price of
       the Combination Product or, if the Licensed Product is not sold
       separately, by the formula C/C+D where C is the fully allocated cost of
       the components of the Combination Product which would constitute a
       Licensed Product and D is the fully allocated cost of the components of
       the Combination Product which perform a function which if performed
       separately would not constitute a Licensed Product.

2.4  "Combination product" means a product which performs more than one
     function, for example, detection of two different organisms or both
     detection of an infectious organism and its resistance to antibiotics, one
     function of which if packaged as a separate product would be a Licensed
     Product and another function of which if packaged as a separate product
     would not be a Licensed Product, i.e., not covered by a claim in

                                      -4-

<PAGE>
     an issued patent or pending patent application licensed under this
     Agreement.

2.5  "Licensed Field of Use" means all fields of use (including, without
     limitation, [***]), excluding:

          (a)  [***]; and

          (b)  [***]

2.6  "Licensed Territory" means the world.

2.7  "Co-Exclusive" means that, subject to Article 4, no other licenses will be
     granted to any party in the Licensed Territory in the Licensed Field other
     than Organon Teknika and GEN-PROBE.

2.8  "Affiliate" means any entity which by means of ownership of a majority of
     voting shares or at least 50% interest in income or otherwise directly or
     indirectly controls, is controlled by or is under common control with
     either party.

3. NOVATION

STANFORD and GEN-PROBE agree that the certain Original Amended License
Agreement is hereby terminated and superseded in its entirety by this License
Agreement. Both parties agree that no further rights or obligations survive
from such superseded certain Original Amended License Agreement.

4. GRANT

4.1  STANFORD hereby grants and GEN-PROBE hereby accepts a license in the
     Licensed Field of Use to make, have made, use, and sell Licensed
     Products(s) in the Licensed Territory.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     - 5 -
<PAGE>
4.2  Said license shall be Co-Exclusive in the Licensed Field of Use for the
     life of the last to expire of Licensed Patent(s).

4.3  GEN-PROBE shall have the right to grant sublicenses to third parties to
     make, have made, use and sell Licensed Product(s) in the Licensed
     Territory.

     4.3.1  Such sublicenses are subject to the restriction that any such
            sublicense shall not be on any terms less favorable to STANFORD than
            the terms of this Agreement and that any sublicensee hereunder shall
            not be permitted to further sublicense.

     4.3.2  Any such sublicense shall also expressly include the provisions of
            Articles 7, 8, and 9 for the benefit of STANFORD.

     4.3.3  Upon termination of this Agreement for any cause, any sublicense
            granted hereunder shall continue with STANFORD provided the
            sublicensee agrees to thereafter assume the obligations of GEN-PROBE
            insofar as they correspond to the scope of the sublicense.

5. GOVERNMENT RIGHTS

This Agreement is subject to all of the terms and conditions of Public Law
96-517 as amended, and GEN-PROBE agrees to take all action necessary on its
part as licensee to enable STANFORD to satisfy its obligation thereunder,
relating to Invention.

6. ROYALTIES

6.1  GEN-PROBE has paid and STANFORD has received license issue fees under the
     Original Amended License Agreement and no further license issue fees are
     due hereunder.

6.2  GEN-PROBE shall pay STANFORD earned royalties on the sale of Licensed
     Product(s) of (i) [***] on GEN-PROBE's Net Sales; and (ii)
     [***] on GEN-PROBE's sublicensee's Net Sales.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     - 6 -
<PAGE>
6.3  Beginning on April 1, 1998, and each April 1 thereafter during the term of
     this Agreement, GEN-PROBE shall pay STANFORD a minimum annual royalty of
     [***]. Said minimum annual royalty payments are nonrefundable, but they are
     creditable to the extent provided in Paragraph 6.4 below.

6.4  Creditable payments under this Agreement pursuant to Paragraph 6.1 and 6.3
     shall be an offset to GEN-PROBE against up to one hundred percent (100%) of
     each earned royalty payment which GEN-PROBE would be required to pay
     pursuant to Paragraph 6.2 until the entire credit is exhausted. Credits of
     [***] accumulated by GEN-PROBE under the Original Amended License Agreement
     will carry forward under this Agreement.

6.5  If this Agreement is not terminated in accordance with other provisions
     hereof, GEN-PROBE's obligation to pay royalties hereunder shall continue
     for so long as GEN-PROBE, by its activities would, but for the license
     granted herein, infringe a valid claim of an unexpired Licensed Patent(s)
     of STANFORD, or practice a valid claim issuing from U.S. application Nos.
     07/845,739, 07/202,978, or 07/064,141, covering said activity which has
     prevailed in the '990 Arbitration over a claim of a Licensed Patent(s).

6.6  The royalty on sales in currencies other than U.S. Dollars shall be
     calculated using the appropriate foreign exchange rate for such currency
     quoted by the Bank of America (San Francisco) foreign exchange desk, on the
     close of business on the last banking day of each calendar quarter. Royalty
     and payments to STANFORD shall be in U.S. Dollars and shall be net of all
     non-U.S. taxes.

6.7  Within thirty (30) days after receipt of a statement from STANFORD,
     GEN-PROBE shall reimburse STANFORD for one-half of the costs incurred after
     the Effective Date by STANFORD in connection with the filing and
     prosecution of all patent applications and maintenance of

                                      -7-

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
     patents corresponding to the Invention, and these costs shall be paid by
     GEN-PROBE.

7. REPORTS, PAYMENTS, AND ACCOUNTING

7.1  Quarterly Royalty Payment and Report. GEN-PROBE shall make written reports
     and royalty payments to STANFORD within ninety (90) days after the end of
     each calendar quarter. This report shall state the number, description, and
     aggregate Net Sales of Licensed Product(s) during such completed calendar
     quarter, and resulting calculation pursuant to Paragraph 6.2 of earned
     royalty payment due STANFORD for such completed calendar quarter.
     Concurrent with the making of each such report, GEN-PROBE shall include
     payment due STANFORD of royalties for the calendar quarter covered by such
     report.

7.2  Accounting. GEN-PROBE agrees to keep records for a period of three (3)
     years showing the manufacturing, sales, use, and other disposition of
     products sold or otherwise disposed of under the license herein granted in
     sufficient detail to enable the royalties payable hereunder by GEN-PROBE to
     be determined, and further agrees to permit its books and records to be
     examined to the extent necessary to verify reports provided for in
     Paragraph 7.1 by an independent certified public accountant, provided that
     such audits occur no more than one (1) time per calendar year and provided
     further that accountants shall report to STANFORD only errors regarding
     calculation of royalties. Such examination is to be made by STANFORD, at
     the expense of STANFORD, except in the event that the results of the audit
     reveal a discrepancy in GEN-PROBE'S favor of ten percent (10%) or more,
     then the audit fees shall be paid by GEN-PROBE.

8. WARRANTY AND NEGATION OF WARRANTIES

8.1  Nothing in this Agreement is or shall be construed as:

                                      -8-

<PAGE>
          (a)  A warranty or representation by STANFORD as to the validity or
               scope of any Licensed Patent(s);

          (b)  A warranty or representation that anything made, used, sold, or
               otherwise disposed of under any license granted in this
               Agreement is or will be free from of patents, copyrights, and
               other rights of third parties;

          (c)  An obligation to bring or prosecute actions or suits against
               third parties for infringement, except to the extent and in the
               circumstances described in Article 12; or

          (d)  Granting by implication, estoppel, or otherwise any licenses
               under patents of STANFORD or other persons other than Licensed
               Patent(s), regardless of whether such patents are dominant or
               subordinate to any Licensed Patent(s).

8.2  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, STANFORD MAKES NO
     REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS
     OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY
     OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED
     PRODUCTS(S) WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER
     RIGHTS OF THIRD PARTIES.

9. INDEMNITY

9.1  GEN-PROBE agrees to indemnify, hold harmless, and defend STANFORD and its
     trustees, officers, employees, students, and agents against any and all
     claims for death, illness, personal injury, property damage, and improper
     business practices arising out of the manufacture, use, sale, or other
     disposition of Invention, Licensed Patent(s), or Licensed Product(s) by
     GEN-PROBE, its sublicensees or their customers.

                                      -9-
<PAGE>
9.2  GEN-PROBE shall at all times comply, through insurance or self-insurance,
     with all statutory workers' compensation and employers' liability
     requirements covering any and all employees with respect to activities
     performed under this Agreement.

9.3  GEN-PROBE shall maintain, beginning on the first day GEN-PROBE or any
     GEN-PROBE sublicensee ships a therapeutics product manufactured by the
     licensed process, commercial general liability insurance, including
     products liability insurance, with minimum limits of liability of $5
     million with reputable and financially secure insurance carrier(s) to cover
     the activities of GEN-PROBE and its sublicensee(s). Any and all such
     policies of insurance described in the previous sentence shall include as
     additional named insureds STANFORD, Stanford Health Services, their
     trustees, directors, officers, employees, students and agents, and shall
     provide that such policies may not, without 30 days prior written notice to
     STANFORD, be cancelled or changed to materially adversely affect any such
     additional named insured's coverage. Such insurance shall be written to
     cover liability of such additional named insureds incurred beginning on the
     first day GEN-PROBE or any GEN-PROBE sublicensee ships a therapeutics
     product manufactured by the licensed process and continuing until five
     years after the term of this Agreement. The parties agree that the coverage
     of GEN-PROBE's liability insurance policy(ies) shall be primary, and that
     the coverage of any STANFORD or Stanford Health Services liability
     insurance policy(ies) shall be excess, with respect to liability
     aggregating up to $5,000,000, and that GEN-PROBE shall cause its liability
     insurance contract(s) to so provide. Upon STANFORD's request, GEN-PROBE
     shall from time to time furnish to STANFORD a certificate listing
     GEN-PROBE's applicable insurance policies and confirming compliance with
     all provisions of this Paragraph.

                                      -10-
<PAGE>
10. MARKING

GEN-PROBE agrees to mark Licensed Product(s) made, sold, or otherwise disposed
of by it under the license granted in this Agreement with the numbers of the
Licensed Patent(s) on the Licensed Products(s)' inserts.

11. PROMOTIONAL ADVERTISING

GEN-PROBE agrees not to identify STANFORD in any promotional advertising or
other promotional materials to be disseminated to the public or any portion
thereof or to use the name of any STANFORD faculty member, employee, or student
or any trademark, service mark, trade name, or symbol of STANFORD or Stanford
Health Services, or that is associated with either of them, without STANFORD'S
prior written consent, except where GEN-PROBE is so required to disclose such
relationship by law, regulation or ordinance.

12. INFRINGEMENT BY OTHERS; PROTECTION OF PATENTS

12.1 STANFORD AND GEN-PROBE shall promptly inform the other of any suspected
     infringement of any Licensed Patent(s) by a third party.

12.2 GEN-PROBE agrees to meet with STANFORD and Organon Teknika B.V. to discuss
     a mutually acceptable course of action prior to commencing any legal
     proceeding against any suspected infringer.

13. COMMERCIAL APPLICATION

As an inducement to STANFORD to enter into this Agreement, GEN-PROBE agrees to
use all reasonable efforts and diligence to proceed with the development,
manufacture, and sale or lease of Licensed Product(s) and to diligently develop
markets for the Licensed Product(s). Notwithstanding the foregoing, nothing
herein shall be construed or interpreted as a limitation on the right of
GEN-PROBE, without being in breach of this Agreement, to improve and/or
reconfigure its products, including any Licensed Products(s),

                                      -11-
<PAGE>
to make use of new or different technology, even though doing so might mean
that such products would not (or no longer) be Licensed Product(s) under this
Agreement.

14. TERMINATION

14.1  GEN-PROBE may terminate this Agreement only if it is not practicing
      Licensed Patent(s) or patents issuing from U.S. application Nos.
      07/845,739,07/202,978, or 07/064/141 (except as limited by Paragraph 14.3)
      by giving STANFORD notice in writing at least thirty (30) days in advance
      of the effective date of termination selected by GEN-PROBE.

14.2  STANFORD may terminate this Agreement (except as limited by Paragraph
      14.3) if GEN-PROBE:

          (a)  Is in material default in payment of royalty or providing of
               reports; or

          (b)  Is in breach of any material provision hereof; or

          (c)  Provides any materially false report; and

      GEN-PROBE fails to remedy any such default, breach, or false report within
      sixty (60) days after written notice hereof by STANFORD.

14.3  Surviving any termination are:

          (a)  GEN-PROBE's obligation to pay royalties accrued or accruable;

          (b)  Any cause of action or claim of GEN-PROBE or STANFORD, accrued or
               to accrue, because of any breach or default by the other party;
               and

          (c)  The provisions or Articles 7, 8, and 9.

14.4  Force Majeure. No liability hereunder shall result to either Party from
      delay in performance caused by force majeure, that is, circumstances
      beyond the reasonable control of the party affected thereby, including,
      without limitation, Acts of God, fire, flood, war, government regulations,
      labor unrest, or shortage of or inability to obtain material or equipment.

                                      -12-
<PAGE>
15.ASSIGNMENT

This Agreement shall not be assignable by GEN-PROBE except to an Affiliate or
to the successor of all or substantially all of its business and assets to
which this Agreement relates resulting from transfer by sale, merger or
consolidation of such business and assets or upon the written consent of
STANFORD.

16.ARBITRATION

16.1  Any controversy arising under or related to this Agreement, or any
      disputed claim by either party against the other under this Agreement
      excluding any dispute relating to patent validity or infringement arising
      under this Agreement, shall upon request of either party be settled by
      arbitration in accordance with the Licensing Agreement Arbitration Rules
      of the American Arbitration Association. Upon request of either party,
      arbitration will be by:

      (a) A third party arbitrator mutually agreed upon in writing by GEN-PROBE
          and STANFORD within thirty (30) days of such arbitration request; or

      (b) A member of the American Arbitration Association.

      Judgment upon the award rendered by the Arbitrator may be entered in any
      court having jurisdiction thereof.

16.2  The parties shall be entitled to discovery in like manner as if the
      arbitration were a civil suit in the California Superior Court; provided,
      however, the arbitrator shall have the full authority to limit the scope
      and amount of discovery and pleadings as he deems proper in order to meet
      the time constraints set forth in Paragraph 16.4 below, and the parties
      agree to cooperate toward such end.

16.3  Any arbitration shall be held at Stanford, California, unless the parties
      hereto mutually agree in writing to another place.

                                      -13-

<PAGE>
16.4 Unless otherwise mutually agreed, any arbitrator chosen hereunder shall be
     a duly licensed patent attorney having experience with biotechnology
     patents and having patent licensing experience, who has not (and whose firm
     has not) represented either party. As a condition to accepting and
     presiding over the arbitration, the arbitrator shall agree to conclude the
     proceedings within 6 months after being named as arbitrator and to render a
     written decision within 45 days after conclusion of the arbitration
     hearing.

16.5 Notwithstanding any preceding portion of this Article 16, no demand for
     arbitration shall be made and no arbitration shall be valid if the time for
     bringing the underlying claim has expired under the applicable statute of
     limitation as determined under California law.

17.NOTICES

All notices under this Agreement shall be deemed to have been fully given when
done in writing and deposited in the United States mail, as follows:

               TO STANFORD:   Office of Technology Licensing
                              Stanford University
                              900 Welch Road, Suite 350
                              Palo Alto, CA 94304-1850

               Attention:     Director

               TO GEN-PROBE:  Gen-Probe, Inc.
                              9880 Campus Point Drive
                              San Diego, CA 92121-1589

               Attention:     President

Either party may change its address upon written notice to the other party.

17.ENTIRE AGREEMENT

This Agreement constitutes the entire agreement and understanding between the
parties and supersedes all prior agreements and understandings with respect to
Licensed Product(s) whether written or oral. No modification or

                                      -14-

<PAGE>
claimed waiver of any of the provisions hereof shall be valid unless in writing
and signed by authorized representatives of the party against whom such
modification or waiver is sought to be enforced.

18. APPLICABLE LAW

This Agreement shall be construed, interpreted, and applied in accordance with
the laws of the State of California.

19. OTHER

19.1  The headings of Articles and Paragraphs in this Agreement are inserted for
      reference only and shall not be deemed a part of the text hereof.

19.2  In the event that any provision of this Agreement shall be determined to
      be unenforceable, all other provisions shall remain in full force and
      effect.

IN WITNESS WHEREOF, the parties hereto have executed Agreement in duplicate
originals by their duly authorized officers or representatives.

GEN-PROBE INC.                          THE BOARD OF TRUSTEES OF THE
                                        LELAND STANFORD JUNIOR
                                        UNIVERSITY

By      /s/ Henry L. Nordhoff            By    /s/
   -------------------------------        -------------------------------------
Title  CEO                              Title  Acting Director
     -----------------------------           ----------------------------------
Date  23-April-97                       Date  April 21, 1997
    ------------------------------          -----------------------------------

[APPROVED LEGAL SEAL]

                                      -15-<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.21

                            NON-ASSERTION AGREEMENT

     This AGREEMENT is made effective this 7th day of February, 1997 by and
between GEN-PROBE INCORPORATED, having a place of business at 9880 Campus Point
Drive, San Diego, California 92121, United States of America ("GEN-PROBE") and
ORGANON TEKNIKA B.V., having a place of business at Boseind 15, 5281 RM Boxtel,
The Netherlands ("TEKNIKA"), who agree as follows:

Section 1.0 Recitals

     1.1  GEN-PROBE and TEKNIKA each possess their own Patent Rights regarding
transcription-based amplification which are listed in Appendix A. GEN-PROBE
holds an exclusive license to the Stanford Patent under the Stanford Agreement.

     1.2  GEN-PROBE and TEKNIKA each desire to avoid legal actions between
themselves relating to each other's Patent Rights and with regard to the
Stanford Patent and to minimize costs associated with possible patent
interference proceedings and other possible adversarial activities in any
national patent office or in the European Patent Office concerning each other's
Patent Rights or the Stanford Patent.

     1.3  GEN-PROBE and TEKNIKA each desire to allow the other party, and
Licensees of the other party, to practice transcription-based amplification with
immunity from legal action for actually or allegedly infringing each other's
Patent Rights.

     1.4  GEN-PROBE and TEKNIKA each desire to resolve any pending disputes
between the two parties concerning Patent Rights or the Stanford Patent, so as
to allow each party to commercialize products based on transcription-based
amplification without threat of legal action from the other party.

Section 2.0 Definitions

     2.1  "GEN-PROBE Patent Rights" shall mean the patents and patent
applications set forth in Appendix A hereto under the heading "GEN-PROBE Patent
Rights", together with any unlisted patents and patent applications from which
any of the listed patents claim priority, and any and all patents that have
issued or in the future issue from the foregoing patents and patent
applications, including utility, model and design patents and certificates of
invention, and all divisionals, continuations, continuations-in-part, reissues,
renewals, re-examinations, extensions or additions thereof claiming priority
from any of the foregoing patents or patent applications heretofore or hereafter
having legal force in any country to the extent that GEN-PROBE has the right to
grant licenses, immunities, or rights thereunder or to assert rights thereunder.

Explicitly and specifically excluded from GEN-PROBE Patent Rights are rights to
specific nucleic acid sequences described in or subsequently claimed by the
above patents and patent applications and all continuations,
continuations-in-part, divisionals, re-examinations, renewals, reissues,
additions, and extensions thereof claiming priority from any of the patents or
patent applications set forth in Appendix
<PAGE>
A heretofore or hereafter having legal force in any country to the extent that
either party has the right to grant licenses, immunities, or rights thereunder
or to assert rights thereunder.

GEN-PROBE shall disclose in Appendix A any limitations on its rights to grant
licenses, immunities, or rights under the GEN-PROBE Patent Rights or to assert
rights thereunder.

     2.2  "TEKNIKA Patent Rights" shall mean the patents and patent applications
set forth in Appendix A hereto under the heading "TEKNIKA Patent Rights",
together with any unlisted patents and patent applications from which any of
the listed patents claim priority, and any and all patents that have issued or
in the future issue from the foregoing patents and patent applications,
including utility, model and design patents and certificates of invention, and
all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions thereof claiming priority from any of the foregoing
patents or patent applications heretofore or hereafter having legal force in
any country to the extent that TEKNIKA has the right to grant licenses,
immunities, or rights thereunder or to assert rights thereunder.

Explicitly and specifically excluded from TEKNIKA Patent Rights are rights to
specific nucleic acid sequences described in or subsequently claimed by the
above patents and patent applications and all continuations,
continuations-in-part, divisionals, re-examinations, renewals, reissues,
additions, and extensions thereof claiming priority from any of the patents or
patent applications set forth in Appendix A heretofore or hereafter having legal
force in any country to the extent that either party has the right to grant
licenses, immunities, or rights thereunder or to assert rights thereunder.

TEKNIKA shall disclose in Appendix A any limitations on its rights to grant
licenses, immunities, or rights under the TEKNIKA Patent Rights or to assert
rights thereunder.

     2.3  "Patent Rights" shall mean GEN-PROBE Patent Rights and/or TEKNIKA
Patent Rights as the context requires.

     2.4  "Stanford Patent" shall mean U.S. Patent 5,437,990 and all
continuations, continuations-in-part, divisionals, re-examinations, renewals,
reissues and extension of patents or patent applications filed in the United
States of America or in any other country which claim priority from or are
derived from U.S. patent application Serial Number 80,479; filed July 31, 1987.

     2.5  "GEN-PROBE Version" shall mean transcription-based nucleic acid
amplification using reverse transcriptase, RNA polymerase and [***] wherein

     (a) the reverse transcriptase and RNase H activities are provided by [***];

     (b) said protein has a minimal reverse transcriptase activity of [***]
         (where the unit definition and assay conditions are equivalent to those
         set forth in Appendix D); and

     (c) the amplification reaction is performed at [***].

     2.6  "TEKNIKA Version" shall mean transcription-based nucleic acid
amplification using reverse transcriptase, RNA polymerase and [***] wherein

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
          (a) [***];

          (b) [***]; and

          (c) the amplification process is performed at [***].

          2.7  "Thermostable Version" shall mean transcription-based nucleic
acid amplification conducted at a temperature of [***].

          2.8  "Version" shall mean the GEN-PROBE Version or the TEKNIKA
Version as the context requires.

          2.9  "Licensees" shall mean parties which are granted licenses by
TEKNIKA or GEN-PROBE to Patent Rights owned or controlled by TEKNIKA or
GEN-PROBE respectively.

          2.10 "Stanford Agreement" shall mean the existing agreement between
GEN-PROBE and Stanford University (effective August 1, 1988: Stanford Docket
S87-012).

          2.11 Insofar as issues regarding alleged infringement of particular
transcription-based amplification processes have not been mutually agreed to by
the parties, and removal of the need to do so is a major purpose of this
Agreement, for simplicity and the mutual convenience of the parties the term
"Product" shall mean a product covered or alleged to be covered by the Stanford
Patent or the Patent Rights listed in Appendix A.

          2.12 "Affiliate" shall mean any corporation, company, or other
business entity which directly or indirectly controls, is controlled by, or is
under common control with a party to this Agreement. For this purpose, control
means ownership or control, either direct or indirect, of at least fifty
percent (50%) of the voting stock or other ownership interest of the other
entity, or the party that directly or indirectly possesses the power to direct
or cause the direction of the management and policies of the other entity by
any means whatsoever.

Section 3.0. Non-Exclusive Immunity Grants

          3.1  GEN-PROBE grants to TEKNIKA, and to TEKNIKA's Affiliates and
Licensees, world-wide, non-exclusive immunity from legal action under the
GEN-PROBE Patent Rights to make, use and/or sell Products based on,
incorporating or utilizing the TEKNIKA Version and/or a Thermostable Version.
GEN-PROBE's grant of immunity under this section shall not be transferable by
said Licensees to additional third parties without GEN-PROBE's prior written
approval.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
          3.2 TEKNIKA grants to GEN-PROBE, and to GEN-PROBE's Affiliates and
Licensees, world-wide, non-exclusive immunity from legal action under the
TEKNIKA Patent Rights to make, use and/or sell Products based on, incorporating
or utilizing the GEN-PROBE Version and/or a Thermostable Version. TEKNIKA's
grant of immunity under this section shall not be transferable by said
Licensees to additional third parties without TEKNIKA's prior written approval.

          3.3. GEN-PROBE agrees not to practice the TEKNIKA Version and TEKNIKA
agrees not to practice the GEN-PROBE Version of transcription-based
amplification, and each agrees in any license to its Patent Rights to require
its Licensees not to practice the other party's Version of transcription-based
amplification.

GEN-PROBE and TEKNIKA each agree to permit at the request of the other party an
annual review of its manufacturing records (and other records as may be
required) by an impartial, technically qualified third party to verify
compliance with the provisions of Section 3.3 of this Agreement. Selection of
such third party shall be subject to the approval of the party whose records
are to be reviewed, such approval to be not unreasonably withheld. The results
of such a review as provided to the requesting party will consist solely of a
finding of compliance or non-compliance. The cost of such review shall be borne
by the requesting party and shall not be unreasonably burdensome for the party
whose records are to be reviewed.

GEN-PROBE and TEKNIKA each agree to include in all licenses which derive
benefits from this Non-Assertion Agreement provisions which permit review of
the Licensee's activities in like manner to the above to permit verification of
compliance by such Licensees with the provisions of Section 3.3.

          3.4 GEN-PROBE agrees not to assert against TEKNIKA, or TEKNIKA's
Affiliates or Licensees, in any jurisdiction the GEN-PROBE Patent Rights, or
any other patent rights which it now or hereafter owns or to which it now or
hereafter otherwise acquires rights that would be infringed by the practice of
the TEKNIKA Version or a Thermostable Version of transcription-based
amplification. The foregoing sentence however expressly shall not prevent or
prohibit GEN-PROBE from asserting any such Patent Rights, or such other patent
rights, to prevent TEKNIKA, or TEKNIKA's Affiliates or Licensees, from
practicing the GEN-PROBE Version of transcription-based amplification.

          3.5 TEKNIKA agrees not to assert against GEN-PROBE, or GEN-PROBE's
Affiliates or Licensees, in any jurisdiction the TEKNIKA Patent Rights, or any
other patent rights which it now or hereafter owns or to which it now or
hereafter otherwise acquires rights that would be infringed by the practice of
the GEN-PROBE Version or a Thermostable Version of transcription-based
amplification. The foregoing sentence however expressly shall not prevent or
prohibit TEKNIKA from asserting any such Patent Rights, or such other patent
rights, to prevent GEN-PROBE, or GEN-PROBE's Affiliates or Licensees, from
practicing the TEKNIKA Version of transcription-based amplification.

          3.6 GEN-PROBE agrees to allow Stanford University to convert
GEN-PROBE's license under the Stanford Agreement from an exclusive license to a
co-exclusive license, and to offer a license to TEKNIKA which shall carry with
it the right to grant sublicenses, provided that:

          (a) TEKNIKA is the only other co-exclusive licensee; and

<PAGE>
          (b) the scope of the co-exclusive license is [***] current license;
          and

          (c) the terms of the aforementioned co-exclusive license concluded
          between TEKNIKA and Stanford University will be made available by
          Stanford University to GEN-PROBE, at GEN-PROBE's option; and

          (d) the terms of the aforementioned co-exclusive license concluded
          between GEN-PROBE and Stanford University will be made available by
          Stanford University to TEKNIKA at TEKNIKA's option.

Prior to concluding the aforementioned co-exclusive license between TEKNIKA and
STANFORD, the immunity under this Agreement shall be limited directly to
GEN-PROBE and TEKNIKA and shall not be available to any licensee of either party
until the aforementioned co-exclusive license between TEKNIKA and STANFORD is
concluded.

          3.7 GEN-PROBE and TEKNIKA each agree that the other party may grant
licenses to third parties under its own Patent Rights, provided that such
licenses include the limitations imposed by this Agreement, including, but not
limited to, Section 3.3. Any and all such licenses shall not carry with them
the right for such third party to grant licenses under either party's Patent
Rights to any other party.

          3.8 Warranty of Disclosure

TEKNIKA and GEN-PROBE each warrant that they have disclosed all rights to
patents and patent applications existing at the time of signature which relate
to transcription-based amplification or could block the practice of the other
party's Version or a Thermostable Version of transcription-based amplification
or claiming thermostable enzymes or their use, or transcription-based
amplification using such enzymes, which they own or have rights to, including
non-exclusive rights or access to, as through licensing, for example.

          3.9 [***]

TEKNIKA and GEN-PROBE each agree that, if either one enters into negotiations
with any party having rights to patents or patent applications covering [***]
for transcription-based amplification as, for example, by virtue of having
filed a patent application to obtain such rights, then TEKNIKA or GEN-PROBE, as
applicable, shall make reasonable efforts to either secure equivalent rights
for the other party directly or secure a right to sub-license such patent
rights. If rights to such patents or patent applications are acquired by either
party, then it shall promptly inform the other of that fact.

If a right to sub-license is acquired by either party, a sub-license of maximum
allowable scope will be provided by such party (the "Sublicensor") to the other
party on commercially reasonable terms and conditions to be negotiated in good
faith.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
In the event that the Sublicensor grants a sublicense to a third party on more
favorable terms and conditions than made available to the other party to this
Agreement, then said other party shall be entitled to avail itself of the same
terms and conditions. Within 30 days of entering into said sublicense with said
third party, the Sublicensor shall inform the other party to this Agreement in
writing of said sublicense and its terms and conditions. Said other party shall
then have the right to enter into, or amend, its own sublicense agreement to
obtain such rights under the same terms and conditions taking into account
investments or expenditures made by the party who has obtained such right of
sublicense.

Section 4.0. Termination of Legal Actions; Defense of Patent Rights

     4.1  Each party shall (i) promptly terminate any and all pending legal
actions and (ii) refrain from initiating any new legal actions concerning
transcription-based amplification which are directed against the other party's
Patent Rights or the Stanford Patent. Such legal actions include, but are not
limited to, actions in any patent office (e.g., oppositions and
re-examinations).

     4.2  Each party agrees to cooperate with the other party to the full
extent permissible by law and good legal practice in order to expeditiously
resolve any patent interference involving the parties with respect to claims
involving the Patent Rights or the Stanford Patent in accordance with the
provisions of Appendix C. The outcome of any interference involving Patent
Rights covering transcription-based amplification owned or licensed by
GEN-PROBE or TEKNIKA, or the Stanford Patent shall be subject to the terms of
this Agreement.

     4.3  Each party shall take any and all actions with respect to the
prosecution and defense of its Patent Rights that it deems appropriate,
(including defending its Patent Rights against infringers) and neither party
shall be responsible to the other party for any such actions that it may take,
or fail to take. Each party shall bear all costs associated with such actions
respecting its own Patent Rights.

     4.4  Either party may request that the other party provide non-financial
assistance in the prosecution and defense of its Patent Rights, and the other
party shall provide such assistance provided the provision of same shall not be
unreasonably burdensome in terms of time, costs and effort.

Section 5.0 Assignment

     5.1  A party shall not assign any of its rights and privileges under this
Agreement without the prior written consent of the other party, except to an
Affiliate or a successor in interest of all or substantially all the assets of
that part of the assigning party's business to which the Patent Rights relate,
which Affiliate or successor assumes in writing the performance of all the
terms and conditions of this Agreement to be performed by the assigning party.
After assignment to a non-Affiliate, the assigning party shall no longer be
immune hereunder. Any assignment shall not in any way affect the immunity,
referred to under Section 3.0 here above, of Licensees of the assigning party.

Section 6.0. Absence of Warranty or Representation

     6.1  Neither party warrants or represents that practicing or using any of
the transcription-based amplification processes which are the subject of this
Agreement does not infringe patents or other

<PAGE>
intellectual property  rights of any third party, and no indemnity against such
infringement is provided by either party to the other. Each party acknowledges
and accepts such absence of warranty or representation from the other party.

Section 7.0. Confidentiality of Agreement Terms

     7.1 The parties hereto agree that they will not discuss the terms and
conditions of this Agreement, nor of any agreement between GEN-PROBE and
Stanford, nor of any agreement between TEKNIKA and Stanford, with any third
party (except as may be required by applicable law, regulation, or court order,
or in connection with the licensing of this transcription-based amplification
technology, but then to the least extent allowable and only on a general basis
without disclosure of financial terms and in any event subject to undertakings
of confidentiality) and they will not make any external public communications
with respect to this Agreement without consulting with and obtaining the prior
written approval of the other party. GEN-PROBE and TEKNIKA agree to include in
like manner in all license agreements with Licensees provisions to the same
effect.

Section 8.0. Future Discussions

     8.1 Each party confirms its willingness to enter into good faith
negotiations to attempt to reach mutual agreement on commercially reasonable
terms and conditions to license to the other party, on a non-exclusive basis,
its technologies or patents listed under Chapter II in Appendix B. Neither party
envisages granting exclusive licenses under Chapter II of Appendix B to a third
party. In the event, however, that either party wishes to initiate negotiations
that would grant an exclusive license to a third party for a patent or
technology listed under Chapter II in Appendix B, for a period of five (5) years
following the signing of this Agreement, such party will not do so without first
discussing with the other party the possibility of licensing to the other party
such patent or technology.

     8.2 The parties also confirm their willingness to discuss mutually
advantageous business arrangements with respect to additional technologies
useful in the framework of this Agreement, which are not included in Appendix A
or Appendix B, that they may develop, or acquire rights to, in the future.

Section 9.0. Joint Negotiations

9.1 TEKNIKA agrees to accept the co-exclusive license referred to in Section 3.6
above under the same terms and conditions as the Stanford Agreement, or on such
more favorable terms as may be negotiated with Stanford. Should Stanford be
unwilling or unable, within 90 days of the signing of this Agreement by both
parties, to offer such co-exclusive license to TEKNIKA on at least the same
terms and conditions as the Stanford Agreement, then either TEKNIKA or GEN-PROBE
may terminate this Agreement.

9.2 Notwithstanding the provisions of Section 7.0 of this Agreement, the parties
acknowledge that certain information concerning this Agreement may need to be
revealed to Stanford in order to convert Gen-Probe's license to a co-exclusive
license as set forth in Section 3.6 of this Agreement. The parties agree that
neither shall reveal any information about this Agreement to Stanford other than
the following, unless otherwise agreed by the parties in writing:
<PAGE>
(1)  GEN-PROBE and TEKNIKA have entered into a provisional non-assertion
agreement that will be finalized when Stanford has made license rights
available to TEKNIKA that are acceptable under the terms of the non-assertion
Agreement.

(2)  GEN-PROBE has agreed to allow Stanford to convert GEN-PROBE's license from
an exclusive license to a co-exclusive license, and to offer a license to
TEKNIKA which shall include the right to grant sublicenses, provided that:

        (a) TEKNIKA is the only other co-exclusive licensee; and

        (b) the scope of the co-exclusive license is [***] current license; and

        (c) the terms of the aforementioned co-exclusive license concluded
between TEKNIKA and Stanford University will be made available by Stanford
University to GEN-PROBE, at GEN-PROBE's option; and

        (d) the terms of the aforementioned co-exclusive license concluded
between GEN-PROBE and Stanford University will be made available by Stanford
University to TEKNIKA, at TEKNIKA's option.

Section 10.    Termination of Agreement

        10.1   This Agreement shall expire on the expiration of the last to
expire Patent Right listed in Appendix A or the Stanford Patent.

        10.2   GEN-PROBE may terminate the obligations under Sections 3.1, 3.4
and 8 in cases in which TEKNIKA is in material breach, and TEKNIKA may terminate
the obligations under Sections 3.2, 3.5, and 8 in cases in which GEN-PROBE is in
material breach, of this Agreement upon or after the breach of any material
provision of this Agreement by the other party, if the other party has cured
such breach within ninety (90) days after written notice thereof by the
non-breaching party. Material breach shall be deemed to include, but not be
limited to, a breach of Sections 3.3, 3.4, 3.5, 3.6, 3.7, 3.9, 4, 5, 8, and 9.1
of this Agreement. Expiration or termination of this Agreement shall not relieve
the parties of any obligation accruing prior to such expiration or termination.

        10.3   Upon termination of this Agreement, as permitted by Section
10.2, the non-breaching party shall grant direct immunity from legal action to
Licensees of the breaching party, under the terms and conditions set forth in
this Agreement, provided that:

        (a) the non-breaching party shall have received express written notice
of the license granted to such Licensee prior to the effective termination date
of this Agreement;

        (b) the Licensee expressly agreed in writing on or before the ninetieth
(90th) day prior to the effective termination date of this Agreement to be
bound by the terms and conditions of this Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
Section 11. Governing Law

     11.1 This Agreement shall be construed, and its performance governed in
accordance with the laws of the State of New York, without regard to the
conflicts of law principles thereof, and, as applicable, the laws of the United
States of America.

Section 12. Arbitration

     12.1 Any dispute, controversy or claim originally initiated by either party
relating to, arising out of or resulting from this Agreement, or the performance
by either party of its obligations hereunder, whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration.
Whenever a party shall decide to institute arbitration proceedings, it shall
have written notice to that effect to the other party. Any arbitration hereunder
shall be conducted under the Rules of Conciliation and Arbitration of the
International Chamber of Commerce. Each such arbitration shall be conducted in
the English language, by a panel of three arbitrators appointed in accordance
with such rules. Any such arbitration shall be held in New York, New York. The
arbitrators shall have the authority to grant specific performance, and to
allocate between the parties and costs of arbitration in such equitable manner
as they determine. Judgment upon the award so rendered may be entered in any
court having jurisdiction or application may be made to such court for judicial
acceptance of any award and an order of enforcement, as the case may be. In no
event shall a demand for arbitration be made after the date when institution of
a legal or equitable proceeding based upon such claim, dispute or other matter
in question would be barred by the applicable statute of limitations under
Section 11. For the avoidance of doubt, the provisions of this Section 12.1 do
not pertain to the arbitration referred to in Appendix C hereto.

Section 13. Entire Understanding

     13.1 This Agreement, and the Appendices A, B, C and D which form an
integral part thereof, embody the entire understanding between the parties and
supersede any prior representations, understandings and agreements between and
among them respecting the subject matter hereof. There are no representations,
agreements, arrangements or understandings, oral or written, between the parties
hereto relating to the subject matter of this Agreement which are not fully
expressed herein.

Section 14. Severability

     14.1 Any of the provisions of this Agreement which are determined to be
invalid or unenforceable in any jurisdiction shall be ineffective to the extent
of such invalidity or unenforceability in such jurisdiction, without rendering
invalid or unenforceable the remaining provisions hereof and without affecting
the validity or enforceability of any of the terms of this Agreement in any
other jurisdiction.
<PAGE>
Section 15. Notices

For TEKNIKA:

     Organon Teknika BV
     Boseind 15
     P.O. Box 84
     5280 AB Boxtel
     The Netherlands
     Attn. President

with copy to:

     Organon Teknika NV
     Veedijk 58
     2300 Turnhout
     Belgium
     Attn. President

For GEN-PROBE:

     Gen-Probe Incorporated
     9880 Campus Point Drive
     San Diego, CA 92121
     Attn. President and CEO

with copy to:

     Gen-Probe Incorporated
     9880 Campus Point Drive
     San Diego, CA 92121
     Atn. General Counsel

All notices required under this Agreement shall be delivered by hand, by United
States mail, or by courier, and a written receipt verifying the date and time
of delivery and to whom delivered shall be obtained by the sender. All such
notices will be deemed to have been delivered at such date and time.

<PAGE>
Either party may change the address for delivery of notices to it by providing
notice to the other party in the manner described.

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first
set forth above.

GEN-PROBE INCORPORATED                       ORGANON TEKNIKA B.V.

By /s/Henry L. Nordhoff                      By /s/ Robert Salsmans
-------------------------                    -----------------------
Henry L. Nordhoff                            Dr. Robert Salsmans
Chairman, President and CEO                  President

                                             By /s/ A.J.F. Stap
                                             -----------------------
                                             A.J.F. Stap
[Approved Legal Stamp]                       Executive Vice President
                                             Corporate Development and
                                                Project Management

<PAGE>
                                   APPENDIX A

                            GEN-PROBE PATENT RIGHTS

<Table>
<Caption>

<S>                 <C>                 <C>                 <C>
                    PR DATE             PR APPL.            PUBL. NO.

[***]
</Table>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                             APPENDIX A (continued)

                             TEKNIKA PATENT RIGHTS

<Table>
<Caption>

<S>                 <C>                 <C>                 <C>
                    PR DATE             PR APPL.            PUBL. NO.

[***]
</TABLE>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                   APPENDIX B

                                   CHAPTER II
                               GEN-PROBE PATENTS

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                             APPENDIX B (Continued)

                                   CHAPTER II
                               GEN-PROBE PATENTS

                                     [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                             APPENDIX B (Continued)

                                TEKNIKA PATENTS

[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                   APPENDIX C

                           Determination of Priority

Two Party Interference

In the event of a two party interference between any of the GEN-PROBE Patent
Rights identified in Appendix A or the Stanford Patent (subject to Stanford's
agreement), and any of the TEKNIKA Patent Rights identified in Appendix A,
priority in such an interference shall be decided as follows.

Immediately upon declaration of said interference, the parties shall negotiate
in good faith for 30 days in an attempt to reach agreement regarding priority.
If agreement cannot be reached within said 30 day period, each party shall,
within 10 additional days, choose one arbitrator, and the two arbitrators chosen
shall, within 10 additional days after being chosen, select the third
arbitrator. Priority shall be determined, to the exclusion of a court of law and
PTO proceedings, by binding arbitration by the panel of three arbitrators in
accordance with the 37 CFR Section 1.690 and USPTO rules in the English
language, in New York, New York within 120 days after selection of the third
arbitrator. The arbitrators shall consider evidence of priority submitted by
each party in accordance with reasonable rules and procedures determined by the
arbitrators. Any party desiring a stenographic record may secure a court
reporter to attend the proceedings. The arbitrators must hold an oral hearing.
Written briefs may be filed up to 7 days before the hearing. All information
disclosed shall be confidential subject to a mutually agreeable protective
order. The award of priority shall be made within 120 days of the selection of
the third arbitrator and shall be based on the evidence introduced, including
all logical and reasonable inferences therefrom. The award must be made in
writing and signed by the arbitrators. It shall contain a concise statement of
the reasons in support of the decision. The decision of the arbitrators shall be
final and binding.

In the event such interference occurs in a country other than the United
States, the parties agree to arbitrate such interference in accordance with the
patent laws of such country.

[***] The decision of the arbitrators shall immediately be filed with the PTO in
accordance with PTO rules. The parties shall also make all necessary disclosures
under 35 U.S.C. Section 135 and applicable PTO rules. The decision of the
arbitrators shall have no effect on the immunities granted in this Agreement.

Multiple Party Interference

In the event of an interference between any of the patents and patent
applications identified in Appendix A and other applications owned by Third
Parties, GEN-PROBE and TEKNIKA shall be entitled to participate in said
interference to a determination of priority or until a settlement involving
all of the parties. Any such determination of priority shall have no effect on
the immunities granted in this Agreement. Upon declaration of such
interference, GEN-PROBE and TEKNIKA will exchange evidence relating to
priority, including, but not limited to, evidence relating to reduction to
practice and conception. Such exchange will be made no later than ten (10) days
prior to the time set for the first disclosure of said dates to the PTO. To the
extent either party is a party to or participates in such interference, it
shall use its best commercially reasonable efforts to win in such interference.
If either GEN-PROBE or TEKNIKA is not a party to such interference, the one
which is a party shall not oppose in any way any attempt by the other to
participate in the interference proceedings. TEKNIKA and GEN-PROBE will file
all necessary agreements (whether relating to the previous sentence or
otherwise) with the PTO in accordance with 35 U.S.C. Section 135. The decision
of the arbitrators shall have no effect on the immunities granted in this
Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                   APPENDIX D
                                 ENZYME ASSAYS

[***]

*** Certain information on this page has been omitted and filed separetely with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]